Proactive Investors - Run By Investors For Investors

PureTech Health affiliate inks major deal with Japanese pharma

The partnership with Shionogi is worth US$20mln upfront and US$105mln in potential milestone payments
ADHD graphic
One of the drugs being developed is for attention deficit disorder

PureTech Health PLC (LON:PRTC) said its affiliate company has inked a major deal with a Japanese pharma worth US$20mln upfront and up to US$105mln in potential milestone payments.

The firm, Akili, is developing digital medicines AKL-T01 and AKL-T02.

The former is currently under review with the US Food and Drug Administration as a potential digital treatment for children with attention-deficit hyperactivity disorder, while the latter is in late-stage trials in children with an autism spectrum disorder.

The partnership with Shionogi & Co covers the markets of Japan and Korea.

View full PRTC profile View Profile

PureTech Health Timeline

January 22 2016

Related Articles

September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use